Ansun Biopharma Announces First Patient Enrolled In Phase 3 Clinical Trial Evaluating DAS181 In Hospitalized, Immunocompromised Patients With Lower Respiratory Tract Parainfluenza Virus Infection - PRNewswire

Ansun Biopharma Announces First Patient Enrolled In Phase 3 Clinical Trial Evaluating DAS181 In Hospitalized, Immunocompromised Patients With Lower Respiratory Tract Parainfluenza Virus Infection  PRNewswire

SAN DIEGO, May 28, 2019 /PRNewswire/ -- Ansun Biopharma, Inc., today announced that the first patient has been enrolled in its Phase 3 clinical trial ...



Comments

Popular posts from this blog

Global Influenzavirus B Infection Drug Market 2019 - AbbVie Inc, Adimmune Corp, Altravax Inc, Amarillo Biosciences Inc, Aphios Corp Business Pulze - Business Pulze

Healthcare layoff tracker—Walmart cuts 74 virtual health jobs - Fierce healthcare